NitroMed

Organization
NitroMed

NitroMed® is an emerging pharmaceutical company that was founded to explore and leverage the therapeutic benefits of nitric oxide, which is thought to play a role in a variety of biological processes. Its first commercialized medicine is BiDil® (isosorbide dinitrate/hydralazine hydrochloride), a fixed-dosed combination tablet available in the US for the adjunct treatment of heart failure (HF) in self-identified black patients.

Articles by author